CLINICAL TRIALS PROFILE FOR OMIDENEPAG ISOPROPYL
✉ Email this page to a colleague
All Clinical Trials for omidenepag isopropyl
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05279716 ↗ | Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl | Recruiting | Santen Pharmaceutical Asia Pte. Ltd. | Phase 4 | 2022-02-15 | This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease. the investigators would like to confirm the real world evidence(RWE) of safety and efficacy after changing to Eybelis ophthalmic solution 0.002%. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for omidenepag isopropyl
Condition Name
Clinical Trial Locations for omidenepag isopropyl
Clinical Trial Progress for omidenepag isopropyl
Clinical Trial Phase
Clinical Trial Sponsors for omidenepag isopropyl
Sponsor Name